ArticleMolecular biology reports2026
Interleukin-1β potentiates transforming growth factor-β-induced fibronectin expression, migration, and invasiveness of mesenchymal-like SK-Hep1 cells via p38 mitogen-activated protein kinase-SMAD2/3 crosstalk.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) progression and metastasis are closely associated with the acquisition and maintenance of a mesenchymal phenotype. The transforming growth factor (TGF)-β/SMAD signaling pathway stabilizes the mesenchymal state of HCC, whereas the inflammatory cytokine interleukin-1β (IL-1β) is abundantly expressed in the HCC tumor microenvironment and activates p38 mitogen-activated protein kinase (MAPK), a key mediator of cell migration and invasion. However, the role of inflammatory cytokines in modulating TGF-β-mediated mesenchymal phenotypes remains unclear. Therefore, this study aimed to determine the function of IL-1β in the regulation of mesenchymal phenotypes in SK-Hep1 cells and elucidate the roles of the TGF-β/SMAD and p38 MAPK signaling pathways. MATERIALS AND
methodsCells were treated with TGF-β1, IL-1β, or both in combination and mesenchymal marker expression was assessed by western blotting and immunofluorescence. Cell migration and invasion were evaluated by wound healing and Matrigel transwell invasion assays. The selective p38 inhibitor SB202190 was used to determine pathway dependency.
resultsTGF-β1 induced fibronectin and N-cadherin expression and increased their migratory and invasive capacities, whereas IL-1β further enhanced these effects. Mechanistically, IL-1β markedly increased the p38 MAPK phosphorylation and enhanced the TGF-β1-mediated SMAD2/3 phosphorylation and nuclear trans-localization. Furthermore, SB202190 decreased fibronectin and N-cadherin expression and reduced the migratory and invasive capacities of SK-Hep1 cells.
conclusionThese results indicate that IL-1β enhances TGF-β1-mediated mesenchymal phenotypes in SK-Hep1 cells via the activation of a p38 MAPK pathway that is associated with TGF-β/SMAD signaling. Considering that inflammation accelerates HCC progression and metastasis by enhancing the mesenchymal phenotype, these findings support further investigation of anti-inflammatory strategies for HCC management.
Indexed as
Identifiers
42747607What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.